Recognition and management of resistant hypertension

Clinical Journal of the American Society of Nephrology

Volumn 12, Issue 3, 2017, Pages 524-535

  Braam, Branko ^a   Taler, Sandra J ^b   Rahman, Mahboob ^c   Fillaus, Jennifer A ^d   Greco, Barbara A ^e   Forman, John P ^f   Reisin, Efrain ^g   Cohen, Debbie L ^h   Saklayen, Mohammad G ⁱ   Hedayati, S Susan ^j  

^a UNIVERSITY OF ALBERTA   (Canada)

^b MAYO CLINIC   (United States)

^c UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^d UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^e BAYSTATE MEDICAL CENTER   (United States)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

^g LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^h UNIVERSITY OF PENNSYLVANIA   (United States)

ⁱ WRIGHT STATE UNIVERSITY   (United States)

^j UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

more..

Author keywords

Antagonists; Antihypertensive Agents; Blood pressure; Cardiovascular disease; Chronic; Chronic kidney disease; Denervation; Diuretics; Humans; Hypertension; Kidney; Life Style; Mineralocorticoid Receptor; Pressoreceptors; Renal denvervation; Renal Insufficiency; Sodium intake

Indexed keywords

AMPHETAMINE DERIVATIVE; ANABOLIC AGENT; ANTIHYPERTENSIVE AGENT; CYCLOSPORIN; DIURETIC AGENT; ERYTHROPOIETIN; GLUCOCORTICOID; MONOAMINE OXIDASE INHIBITOR; NORADRENALIN UPTAKE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TACROLIMUS; MINERALOCORTICOID ANTAGONIST;

ARTICLE; BLOOD PRESSURE MONITORING; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; END STAGE RENAL DISEASE; FIBROMUSCULAR DYSPLASIA; HEART FAILURE; HIGH RISK POPULATION; HUMAN; ISCHEMIC HEART DISEASE; LIFESTYLE MODIFICATION; MASS SPECTROMETRY; MORTALITY; OXIMETRY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; POLYSOMNOGRAPHY; PREVALENCE; PRIMARY MEDICAL CARE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RESISTANT HYPERTENSION; SENSITIVITY AND SPECIFICITY; SLEEP DISORDERED BREATHING; COMBINATION DRUG THERAPY; COMPLICATION; CORONARY ARTERY SPASM; DIET; ELECTROTHERAPY; HYPERTENSION; LIFESTYLE; PATIENT COMPLIANCE; SYMPATHECTOMY;

ANTIHYPERTENSIVE AGENTS; CORONARY VASOSPASM; DIET; DIURETICS; DRUG THERAPY, COMBINATION; ELECTRIC STIMULATION THERAPY; HUMANS; HYPERTENSION; LIFE STYLE; MINERALOCORTICOID RECEPTOR ANTAGONISTS; PATIENT COMPLIANCE; RENAL INSUFFICIENCY, CHRONIC; SYMPATHECTOMY;

EID: 85020713618     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.06180616     Document Type: Article

References (101)

1. Egan BM, Zhao Y, Axon RN, Brzezinski WA, Ferdinand KC: Uncontrolled and apparent treatment resistant hypertension in the United States, 1988 to 2008. Circulation 124: 1046–1058, 2011
2. McAlister FA, Wilkins K, Joffres M, Leenen FH, Fodor G, Gee M, Tremblay MS, Walker R, Johansen H, Campbell N: Changes in the rates of awareness, treatment and control of hypertension in Canada over the past two decades. CMAJ 183: 1007–1013, 2011
3. Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, White A, Cushman WC, White W, Sica D, Ferdinand K, Giles TD, Falkner B, Carey RM; American Heart Association Professional Education Committee: Resistant hypertension: Diagnosis, evaluation, and treatment:A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation 117: e510–e526, 2008
4. Weitzman D, Chodick G, Shalev V, Grossman C, Grossman E: Prevalence and factors associated with resistant hypertension in a large health maintenance organization in Israel. Hypertension 64: 501–507, 2014
5. Gifford RW Jr.: Resistant hypertension. Introduction and definitions. Hypertension 11: II65–II66, 1988
6. ESH/ESC Task Force for the Management of Arterial Hypertension: 2013 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC): ESH/ESC Task Force for the Management of Arterial Hypertension. J Hypertens 31: 1925–1938, 2013
7. Kumbhani DJ, Steg PG, Cannon CP, Eagle KA, Smith SC Jr., Crowley K, Goto S, Ohman EM, Bakris GL, Perlstein TS, Kinlay S, Bhatt DL; REACH Registry Investigators: Resistant hypertension: A frequent and ominous finding among hypertensive patients with athero-thrombosis. Eur Heart J 34: 1204–1214, 2013
8. Bangalore S, Fayyad R, Laskey R, Demicco DA, Deedwania P, Kostis JB, Messerli FH; Treating to New Targets Steering Committee and Investigators: Prevalence, predictors, and outcomes in treatment-resistant hypertension in patients with coronary disease. Am J Med 127: 71–81.e1, 2014
9. Cushman WC, Ford CE, Cutler JA, Margolis KL, Davis BR, Grimm RH, Black HR, Hamilton BP, Holland J, Nwachuku C, Papademetriou V, Probstfield J, Wright JT Jr., Alderman MH, Weiss RJ, Piller L, Bettencourt J, Walsh SM; ALLHAT Collaborative Research Group: Success and predictors of blood pressure control in diverse North American settings: The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALL-HAT). J Clin Hypertens (Greenwich) 4: 393–404, 2002
10. De Nicola L, Gabbai FB, Agarwal R, Chiodini P, Borrelli S, Bellizzi V, Nappi F, Conte G, Minutolo R: Prevalence and prognostic role of resistant hypertension in chronic kidney disease patients. J Am Coll Cardiol 61: 2461–2467, 2013
11. Gupta AK, Nasothimiou EG, Chang CL, Sever PS, Dahlöf B, Poulter NR; ASCOTinvestigators: Baseline predictors of resistant hypertension in the Anglo-Scandinavian Cardiac Outcome Trial (ASCOT): A risk score to identify those at high-risk. J Hypertens 29: 2004–2013, 2011
12. Muntner P, Davis BR, Cushman WC, Bangalore S, Calhoun DA, Pressel SL, Black HR, Kostis JB, Probstfield JL, Whelton PK, Rahman M; ALLHAT Collaborative Research Group: Treatment-resistant hypertension and the incidence of cardiovascular disease and end-stage renal disease: Results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Hypertension 64: 1012–1021, 2014
13. Persell SD: Prevalence of resistant hypertension in the United States, 2003-2008. Hypertension 57: 1076–1080, 2011
14. Smith SM, Gong Y, Handberg E, Messerli FH, Bakris GL, Ahmed A, Bavry AA, Pepine CJ, Cooper-Dehoff RM: Predictors and outcomes of resistant hypertension among patients with coronary artery disease and hypertension. J Hypertens 32: 635–643, 2014
15. de la Sierra A, Segura J, Banegas JR, Gorostidi M, de la Cruz JJ, Armario P, Oliveras A, Ruilope LM: Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. Hypertension 57: 898– 902, 2011
16. Egan BM, Zhao Y, Li J, Brzezinski WA, Todoran TM, Brook RD, Calhoun DA: Prevalence of optimal treatment regimens in patients with apparent treatment-resistant hypertension based on office blood pressure in a community-based practice network. Hypertension 62: 691–697, 2013
17. Thomas G, Xie D, Chen HY, Anderson AH, Appel LJ, Bodana S, Brecklin CS, Drawz P, Flack JM, Miller ER 3rd, Steigerwalt SP, Townsend RR, Weir MR, Wright JT Jr., Rahman M; CRIC Study Investigators: Prevalence and prognostic significance of apparent treatment resistant hypertension in chronic kidney disease: Report from the Chronic Renal Insufficiency Cohort Study. Hypertension 67: 387–396, 2016
18. de Beus E, Bots ML, van Zuilen AD, Wetzels JF, Blankestijn PJ; MASTERPLAN Study Group: Prevalence of apparent therapy-resistant hypertension and its effect on outcome in patients with chronic kidney disease. Hypertension 66: 998–1005, 2015
19. Daugherty SL, Powers JD, Magid DJ, Tavel HM, Masoudi FA, Margolis KL, O’Connor PJ, Selby JV, Ho PM: Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation 125: 1635–1642, 2012
20. Pickering TG, Hall JE, Appel LJ, Falkner BE, Graves JW, Hill MN, Jones DH, Kurtz T, Sheps SG, Roccella EJ; Council on High Blood Pressure Research Professional and Public Education Subcommittee, American Heart Association: Recommendations for blood pressure measurement in humans: An AHA scientific statement from the Council on High Blood Pressure Research Professional and Public Education Subcommittee. J Clin Hypertens (Greenwich) 7: 102–109, 2005
21. Agencyfor Healthcare Researchand Quality: Screening for High Blood Pressure in Adults: A Systematic Evidence Review for the U.S. Preventive Services Task Force, Rockville, MD, Agency for Healthcare Research and Quality, 2014
22. Fan HQ, Li Y, Thijs L, Hansen TW, Boggia J, Kikuya M, Björklund-Bodegård K, Richart T, Ohkubo T, Jeppesen J, Torp-Pedersen C, Dolan E, Kuznetsova T, Stolarz-Skrzypek K, Tikhonoff V, Malyutina S, Casiglia E, Nikitin Y, Lind L, Sandoya E, Kawecka-Jaszcz K, Imai Y, Ibsen H, O’Brien E, Wang J, Staessen JA; International Database on Ambulatory Blood Pressure In Relation to Cardiovascular Outcomes Investigators: Prognostic value of isolated nocturnal hypertension on ambulatory measurement in 8711 individuals from 10 populations. J Hypertens 28: 2036–2045, 2010
23. Campese VM, Mitra N, Sandee D: Hypertension in renal parenchymal disease: Why is it so resistant to treatment? Kidney Int 69: 967–973, 2006
24. Lurbe E, Redon J, Kesani A, Pascual JM, Tacons J, Alvarez V, Batlle D: Increase in nocturnal blood pressure and progression to microalbuminuria in type 1 diabetes. N Engl J Med 347: 797– 805, 2002
25. Davidson MB, Hix JK, Vidt DG, Brotman DJ: Association of impaired diurnal blood pressure variation with a subsequent decline in glomerular filtration rate. Arch Intern Med 166: 846–852, 2006
26. Ambrosi P, Kreitmann B, Habib G: Home blood pressure monitoring in heart transplant recipients: Comparison with ambulatory blood pressure monitoring. Transplantation 97: 363–367, 2014
27. White WB, Turner JR, Sica DA, Bisognano JD, Calhoun DA, Townsend RR, Aronow HD, Bhatt DL, Bakris GL: Detection, evaluation, and treatment of severe and resistant hypertension: Proceedings from an American Society of Hypertension Interactive forum held in Bethesda, MD, U.S.A., October 10th 2013. J Am Soc Hypertens 8: 743–757, 2014
28. Jung O, Gechter JL, Wunder C, Paulke A, Bartel C, Geiger H, Toennes SW: Resistant hypertension? Assessment of adherence by toxicological urine analysis. J Hypertens 31: 766–774, 2013
29. Tomaszewski M, White C, Patel P, Masca N, Damani R, Hepworth J, Samani NJ, Gupta P, Madira W, Stanley A, Williams B: High rates of non-adherence to antihypertensive treatment revealed by high-performance liquid chromatography-tandem mass spectrometry (HP LC-MS/MS) urine analysis. Heart 100: 855–861, 2014
30. Schmitt KE, Edie CF, Laflam P, Simbartl LA, Thakar CV: Adherence to antihypertensive agents and blood pressure control in chronic kidney disease. Am J Nephrol 32: 541–548, 2010
31. Burnier M, Schneider MP, Chioléro A, Stubi CL, Brunner HR: Electronic compliance monitoring in resistant hypertension: The basis for rational therapeutic decisions. J Hypertens 19: 335– 341, 2001
32. Mattsson C, Young WF Jr.: Primary aldosteronism: Diagnostic and treatment strategies. Nat Clin Pract Nephrol 2: 198–208, 2006
33. Pandey A, Raza F, Velasco A, Brinker S, Ayers C, Das SR, Morisky DE, Halm EA, Vongpatanasin W: Comparison of morisky medication adherence scale with therapeutic drug monitoring in apparent treatment-resistant hypertension. J Am Soc Hypertens 9: 420–426, 2015
34. Osterberg L, Blaschke T: Adherence to medication. N Engl J Med 353: 487–497, 2005
35. Hameed MA, Tebbit L, Jacques N, Thomas M, Dasgupta I: Non-adherence to antihypertensive medication is very common among resistant hypertensives: Results of a directly observed therapy clinic. J Hum Hypertens 30: 83–89, 2016
36. Trinquart L, Mounier-Vehier C, Sapoval M, Gagnon N, Plouin PF: Efficacy of revascularization for renal artery stenosis caused by fibromuscular dysplasia: Asystematic reviewand meta-analysis. Hypertension 56: 525–532, 2010
37. Harding SM: Prediction formulae for sleep-disordered breathing. Curr Opin Pulm Med 7: 381–385, 2001
38. Abdel-Kader K, Dohar S, Shah N, Jhamb M, Reis SE, Strollo P, Buysse D, Unruh ML: Resistant hypertension and obstructive sleep apnea in the setting of kidney disease. J Hypertens 30: 960– 966, 2012
39. Pedrosa RP, Drager LF, de Paula LK, Amaro AC, Bortolotto LA, Lorenzi-Filho G: Effects of OSA treatment on BP in patients with resistant hypertension: A randomized trial. Chest 144: 1487– 1494, 2013
40. Fava C, Dorigoni S, Dalle Vedove F, Danese E, Montagnana M, Guidi GC, Narkiewicz K, Minuz P: Effect of CPAP on blood pressure in patients with OSA/hypopnea a systematic reviewand meta-analysis. Chest 145: 762–771, 2014
41. Chirinos JA, Gurubhagavatula I, Teff K, Rader DJ, Wadden TA, Townsend R, Foster GD, Maislin G, Saif H, Broderick P, Chittams J, Hanlon AL, Pack AI: CPAP, weight loss, or both for obstructive sleep apnea. N Engl J Med 370: 2265–2275, 2014
42. Nishizaka MK, Pratt-Ubunama M, Zaman MA, Cofield S, Calhoun DA: Validity of plasma aldosterone-to-renin activity ratio in African American and white subjects with resistant hypertension. Am J Hypertens 18: 805–812, 2005
43. Rossignol P, Massy ZA, Azizi M, Bakris G, Ritz E, Covic A, Goldsmith D, Heine GH, Jager KJ, Kanbay M, Mallamaci F, Ortiz A, Vanholder R, Wiecek A, Zoccali C, London GM, Stengel B, Fouque D; ERA-EDTA EURECA-m working group; Red de In-vestigación Renal (REDINREN) network; Cardiovascular and Renal Clinical Trialists (F-CRIN INI-CRCT) network: The double challenge of resistant hypertension and chronic kidney disease. Lancet 386: 1588–1598, 2015
44. Appel LJ, Champagne CM, Harsha DW, Cooper LS, Obarzanek E, Elmer PJ, Stevens VJ, Vollmer WM, Lin PH, Svetkey LP, Stedman SW, Young DR; Writing Group of the PREMIER Collaborative Research Group: Effects of comprehensive lifestyle modification on blood pressure control: Main results of the PREMIER clinical trial. JAMA 289: 2083–2093, 2003
45. Appel LJ, Moore TJ, Obarzanek E, Vollmer WM, Svetkey LP, Sacks FM, Bray GA, Vogt TM, Cutler JA, Windhauser MM, Lin PH, Karanja N; DASH Collaborative Research Group: A clinical trial of the effects of dietary patterns on blood pressure. NEngl J Med 336: 1117–1124, 1997
46. Cook NR, Kumanyika SK, Cutler JA, Whelton PK; Trials of Hypertension Prevention Collaborative Research Group: Dose-response of sodium excretion and blood pressure change among overweight, nonhypertensive adults in a 3-year dietary intervention study. J Hum Hypertens 19: 47–54, 2005
47. Hedayati SS, Elsayed EF, Reilly RF: Non-pharmacological aspects of blood pressure management: What are the data? Kidney Int 79: 1061–1070, 2011
48. Miller ER 3rd, Erlinger TP, Young DR, Jehn M, Charleston J, Rhodes D, Wasan SK, Appel LJ: Results of the Diet, Exercise, and Weight Loss Intervention Trial (DEW-IT). Hypertension 40: 612– 618, 2002
49. The Trials of Hypertension Prevention Collaborative Research Group: Effects of weight loss and sodium reduction intervention on blood pressure and hypertension incidence in overweight people with high-normal blood pressure. The trials of hypertension prevention, phase II. Arch Intern Med 157: 657–667, 1997
50. Semlitsch T, Jeitler K, Berghold A, Horvath K, Posch N, Poggenburg S, Siebenhofer A: Long-term effects of weight-reducing diets in people with hypertension. Cochrane Database Syst Rev 3: CD008274, 2016
51. Poirier P, Cornier MA, Mazzone T, Stiles S, Cummings S, Klein S, McCullough PA, Ren Fielding C, Franklin BA; American Heart Association Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism: Bariatric surgery and cardiovascular risk factors: A scientific statement from the American Heart Association. Circulation 123: 1683–1701, 2011
52. Sjöström CD, Peltonen M, Sjöström L: Blood pressure and pulse pressure during long-term weight loss in the obese: The Swedish Obese Subjects (SOS) Intervention Study. Obes Res 9: 188–195, 2001
53. Sjöström CD, Peltonen M, Wedel H, Sjöström L: Differentiated long-term effects of intentional weight loss on diabetes and hypertension. Hypertension 36: 20–25, 2000
54. Courcoulas AP, Christian NJ, Belle SH, Berk PD, Flum DR, Garcia L, Horlick M, Kalarchian MA, King WC, Mitchell JE, Patterson EJ, Pender JR, Pomp A, Pories WJ, Thirlby RC, Yanovski SZ, Wolfe BM; Longitudinal Assessment of Bariatric Surgery (LABS) Consortium: Weight change and health outcomes at 3 years after bariatric surgery among individuals with severe obesity. JAMA 310: 2416–2425, 2013
55. Bonfils PK, Taskiran M, Damgaard M, Goetze JP, Floyd AK, Funch-Jensen P, Kristiansen VB, Støckel M, Bouchelouche PN, Gadsbøll N: Roux-en-Y gastric bypass alleviates hypertension and is associated with an increase in mid-regional pro-atrial natriuretic peptide in morbid obese patients. J Hypertens 33: 1215–1225, 2015
56. McLean DL, McAlister FA, Johnson JA, King KM, Makowsky MJ, Jones CA, Tsuyuki RT; SCRIP-HTN Investigators: A randomized trial of the effect of community pharmacist and nurse care on improving blood pressure management in patients with diabetes mellitus: Study of cardiovascular risk intervention by pharma-cists-hypertension (SCRIP-HTN). Arch Intern Med 168: 2355– 2361, 2008
57. Logan AG, Irvine MJ, McIsaac WJ, Tisler A, Rossos PG, Easty A, Feig DS, Cafazzo JA: Effect of home blood pressure telemonitoring with self-care support on uncontrolled systolic hypertension in diabetics. Hypertension 60: 51–57, 2012
58. McKinstry B, Hanley J, Wild S, Pagliari C, Paterson M, Lewis S, Sheikh A, Krishan A, Stoddart A, Padfield P: Telemonitoring based service redesign for the management of uncontrolled hypertension: Multicentre randomised controlled trial. BMJ 346: f3030, 2013
59. Blumenthal JA, Sherwood A, Smith PJ, Mabe S, Watkins L, Lin PH, Craighead LW, Babyak M, Tyson C, Young K, Ashworth M, Kraus W, Liao L, Hinderliter A: Lifestyle modification for resistant hypertension: The TRIUMPH randomized clinical trial. Am Heart J 170: 986–994.e5, 2015
60. Brook RD, Appel LJ, Rubenfire M, Ogedegbe G, Bisognano JD, Elliott WJ, Fuchs FD, Hughes JW, Lackland DT, Staffileno BA, Townsend RR, Rajagopalan S; American Heart Association Professional Education Committee of the Council for High Blood Pressure Research, Council on Cardiovascular and Stroke Nursing, Council on Epidemiology and Prevention, and Council on Nutrition, Physical Activity: Beyond medications and diet: Alternative approaches to lowering blood pressure: A scientific statement from the american heart association. Hypertension 61: 1360–1383, 2013
61. Pimenta E, Oparil S: Prehypertension: Epidemiology, consequences and treatment. Nat Rev Nephrol 6: 21–30, 2010
62. Jolles EP, Clark AM, Braam B: Getting the message across: Opportunities and obstacles in effective communication in hypertension care. J Hypertens 30: 1500–1510, 2012
63. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, Lackland DT, LeFevre ML, MacKenzie TD, Ogedegbe O, Smith SC Jr., Svetkey LP, Taler SJ, Townsend RR, Wright JT Jr., Narva AS, Ortiz E: 2014 evidence-based guideline for the management of high blood pressure in adults: Report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 311: 507–520, 2014
64. Vasavada N, Agarwal R: Role of excess volume in the pathophysiology of hypertension in chronic kidney disease. Kidney Int 64: 1772–1779, 2003
65. Gaddam KK, Nishizaka MK, Pratt-Ubunama MN, Pimenta E, Aban I, Oparil S, Calhoun DA: Characterization of resistant hypertension: Association between resistant hypertension, aldosterone, and persistent intravascular volume expansion. Arch Intern Med 168: 1159–1164, 2008
66. Huang X, Dorhout Mees E, Vos P, Hamza S, Braam B: Everything we always wanted to know about furosemide but were afraid to ask. Am J Physiol Renal Physiol 310: F958–F971, 2016
67. Engbaek M, Hjerrild M, Hallas J, Jacobsen IA: The effect of low-dose spironolactone on resistant hypertension. J Am Soc Hypertens 4: 290–294, 2010
68. Václavík J, Sedlák R, Jarkovský J, Kociánová E, Táborský M: Effect of spironolactone in resistant arterial hypertension: A randomized, double-blind, placebo-controlled trial (ASPIRANT-EXT). Medicine (Baltimore) 93: e162, 2014
69. Williams B, MacDonald TM, Morant S, Webb DJ, Sever P, McInnes G, Ford I, Cruickshank JK, Caulfield MJ, Salsbury J, Mackenzie I, Padmanabhan S, Brown MJ; British Hypertension Society’s PATHWAY Studies Group: Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): A randomised, double-blind, crossover trial. Lancet 386: 2059– 2068, 2015
70. Judd E, Calhoun DA: Management of hypertension in CKD: Beyond the guidelines. Adv Chronic Kidney Dis 22: 116–122, 2015
71. Essig M, Escoubet B, de Zuttere D, Blanchet F, Arnoult F, Dupuis E, Michel C, Mignon F, Mentre F, Clerici C, Vrtovsnik F: Cardiovascular remodelling and extracellular fluid excess in early stages of chronic kidney disease. Nephrol Dial Transplant 23: 239–248, 2008
72. Hung SC, Kuo KL, Peng CH, Wu CH, Lien YC, Wang YC, Tarng DC: Volume overload correlates with cardiovascular risk factors in patients with chronic kidney disease. Kidney Int 85: 703–709, 2014
73. Verdalles U, de Vinuesa SG, Goicoechea M, Quiroga B, Reque J, Panizo N, Arroyo D, Lu~no J: Utility of bioimpedance spectroscopy (BIS) in the management of refractory hypertension in patients with chronic kidney disease (CKD). Nephrol Dial Transplant 27[Suppl 4]: iv31–iv35, 2012
74. Smith RD, Levy P, Ferrario CM; Consideration of Noninvasive Hemodynamic Monitoring to Target Reduction of Blood Pressure Levels Study Group: Value of noninvasivehemodynamics to achieve blood pressure control in hypertensive subjects. Hypertension 47: 771–777, 2006
75. Taler SJ, Textor SC, Augustine JE: Resistant hypertension: Comparing hemodynamic management to specialist care. Hypertension 39: 982–988, 2002
76. Krzesińnski P, Gielerak GG, Kowal JJ: A “patient-tailored” treatment of hypertension with use of impedance cardiography: A randomized, prospective and controlled trial. Med Sci Monit 19: 242–250, 2013
77. Arcand J, Abdulaziz K, Bennett C, L’abbé MR, Manuel DG: Developing a Web-based dietary sodium screening tool for personalized assessment and feedback. Appl Physiol Nutr Metab 39: 413–414, 2014
78. Bax L, Woittiez AJ, Kouwenberg HJ, Mali WP, Buskens E, Beek FJ, Braam B, Huysmans FT, Schultze Kool LJ, Rutten MJ, Doorenbos CJ, Aarts JC, Rabelink TJ, Plouin PF, Raynaud A, van Montfrans GA, Reekers JA, van den Meiracker AH, Pattynama PM, van de Ven PJ, Vroegindeweij D, Kroon AA, de Haan MW, Postma CT, Beutler JJ: Stent placement in patients with atherosclerotic renal artery stenosis and impaired renal function: A randomized trial. Ann Intern Med 150: 840–848, 2009
79. Wheatley K, Ives N, Gray R, Kalra PA, Moss JG, Baigent C, Carr S, Chalmers N, Eadington D, Hamilton G, Lipkin G, Nicholson A, Scoble J, Scoble J; ASTRAL Investigators: Revascularization versus medical therapy for renal-artery stenosis. N Engl J Med 361: 1953–1962, 2009
80. Cooper CJ, Murphy TP, Cutlip DE, Jamerson K, Henrich W, Reid DM, Cohen DJ, Matsumoto AH, Steffes M, Jaff MR, Prince MR, Lewis EF, Tuttle KR, Shapiro JI, Rundback JH, Massaro JM, D’Agostino RB Sr., Dworkin LD; CORAL Investigators: Stenting and medical therapy for atherosclerotic renal-artery stenosis. N Engl J Med 370: 13–22, 2014
81. Hirsch AT, Haskal ZJ, Hertzer NR, Bakal CW, Creager MA, Halperin JL, Hiratzka LF, Murphy WR, Olin JW, Puschett JB, Rosenfield KA, Sacks D, Stanley JC, Taylor LM Jr., White CJ, White J, White RA, Antman EM, Smith SC Jr., Adams CD, Anderson JL, Faxon DP, Fuster V, Gibbons RJ, Hunt SA, Jacobs AK, Nishimura R, Ornato JP, Page RL, Riegel B; American Association for Vascular Surgery; Society for Vascular Surgery; Society for Cardiovascular Angiography and Interventions; Society for Vascular Medicine and Biology; Society of Interventional Radiology; ACC/AHA Task Force on Practice Guidelines Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease; American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; Vascular Disease Foundation: ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): A collaborative report from the American Association for Vascular Surgery/ Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation 113: e463–e654, 2006
82. KDIGO Kidney Blood Pressure Working Group: KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int Suppl 2: 337–414, 2012
83. Pimenta E, Gaddam KK, Oparil S, Aban I, Husain S, Dell’Italia LJ, Calhoun DA: Effects of dietary sodium reduction on blood pressure in subjects with resistant hypertension: Results from a randomized trial. Hypertension 54: 475–481, 2009
84. Gregory LF Jr., Durrett RR, Robinson RR, Clapp JR: The short-term effect of furosemide on electrolyte and water excretion in patients with severe renal disease. Arch Intern Med 125: 69–74, 1970
85. Peterzan MA, Hardy R, Chaturvedi N, Hughes AD: Meta-analysis of dose-response relationships for hydrochlorothiazide, chlorthalidone, and bendroflumethiazide on blood pressure, serum potassium, and urate. Hypertension 59: 1104–1109, 2012
86. Roush GC, Holford TR, Guddati AK: Chlorthalidone compared with hydrochlorothiazide in reducing cardiovascular events: Systematic review and network meta-analyses. Hypertension 59: 1110–1117, 2012
87. Olde Engberink RH, Frenkel WJ, van den Bogaard B, Brewster LM, Vogt L, van den Born BJ: Effects of thiazide-type and thiazide-like diuretics on cardiovascular events and mortality: Systematic review and meta-analysis. Hypertension 65: 1033– 1040, 2015
88. Ernst ME, Carter BL, Goerdt CJ, Steffensmeier JJ, Phillips BB, Zimmerman MB, Bergus GR: Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure. Hypertension 47: 352–358, 2006
89. Sinha AD, Agarwal R: Thiazide diuretics in chronic kidney disease. Curr Hypertens Rep 17: 13, 2015
90. Grassi G: Assessment of sympathetic cardiovascular drive in human hypertension: Achievements and perspectives. Hypertension 54: 690–697, 2009
91. Ayman D, Goldshine AD: Blood-pressure determinations in patients with essential hypertension. III. Evaluation of sympa-thectomy over a three-year to five-year period. N Engl J Med 229: 799–811, 1943
92. Krum H, Schlaich M, Whitbourn R, Sobotka PA, Sadowski J, Bartus K, Kapelak B, Walton A, Sievert H, Thambar S, Abraham WT, Esler M: Catheter-based renal sympathetic denervation for resistant hypertension: A multicentre safety and proof-of-principle cohort study. Lancet 373: 1275–1281, 2009
93. Pokushalov E, Romanov A, Corbucci G, Artyomenko S, Baranova V, Turov A, Shirokova N, Karaskov A, Mittal S, Steinberg JS: A randomized comparison of pulmonary vein isolation with versus without concomitant renal artery denervation in patients with refractory symptomatic atrial fibrillation and resistant hypertension. J Am Coll Cardiol 60: 1163– 1170, 2012
94. Bhatt DL, Kandzari DE, O’Neill WW, D’Agostino R, Flack JM, Katzen BT, Leon MB, Liu M, Mauri L, Negoita M, Cohen SA, Oparil S, Rocha-Singh K, Townsend RR, Bakris GL; SYMPLICITY HTN-3 Investigators: A controlled trial of renal denervation for resistant hypertension. N Engl J Med 370: 1393–1401, 2014
95. Azizi M, Sapoval M, Gosse P, Monge M, Bobrie G, Delsart P, Midulla M, Mounier-Véhier C, Courand PY, Lantelme P, Denolle T, Dourmap-Collas C, Trillaud H, Pereira H, Plouin PF, Chatellier G; Renal Denervation for Hypertension (DENERHTN) investigators: Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): A multicentre, open-label, randomised controlled trial. Lancet 385: 1957–1965, 2015
96. Neuzil P, Ormiston J, Brinton TJ, Starek Z, Esler M, Dawood O, Anderson TL, Gertner M, Whitbourne R, Schmieder RE: Externally delivered focused ultrasound for renal denervation. JACC Cardiovasc Interv 9: 1292–1299, 2016
97. Mahfoud F, Schlaich M, Kindermann I, Ukena C, Cremers B, Brandt MC, Hoppe UC, Vonend O, Rump LC, Sobotka PA, Krum H, Esler M, Böhm M: Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension: A pilot study. Circulation 123: 1940–1946, 2011
98. Ott C, Mahfoud F, Schmid A, Ditting T, Veelken R, Ewen S, Ukena C, Uder M, Böhm M, Schmieder RE: Improvement of albuminuria after renal denervation. Int J Cardiol 173: 311–315, 2014
99. Witkowski A, Prejbisz A, Florczak E, Kądziela J, Śliwińnski P, Bieleńn P, Michałowska I, Kabat M, Warchoł E, Januszewicz M, Narkiewicz K, Somers VK, Sobotka PA, Januszewicz A: Effects of renal sympathetic denervation on blood pressure, sleep apnea course, and glycemic control in patients with resistant hypertension and sleep apnea. Hypertension 58: 559–565, 2011
100. Wang Y: What is the true incidence of renal artery stenosis after sympathetic denervation? Front Physiol 5: 311, 2014
101. Bisognano JD, Bakris G, Nadim MK, Sanchez L, Kroon AA, Schafer J, de Leeuw PW, Sica DA: Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: Results from the double-blind, randomized, placebo-controlled rheos pivotal trial. J Am Coll Cardiol 58: 765–773, 2011